Treatment of KRAS-mutated cancers
JP2024500288A5Inactive Publication Date: 2024-11-27MEI PHARMA INC
0 Cites 0 Cited by
Patent Information
- Application Number
- JP2023530278
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-04-10
- Filing Date
- 2021-11-19
- Publication Date
- 2024-11-27
- Estimated Expiration
- Not applicable · inactive patent
Abstract
The disclosure herein provides combination therapy for the treatment of KRAS mutant cancer. The disclosure relates to a CDK inhibitor, such as a CDK inhibitor represented by formula I: or a pharma- ceutically acceptable salt thereof and an additional therapeutic agent, for example, an anti-cancer agent. JPEG2024500288000053.jpg4143
Need to check novelty before this filing date? Find Prior Art
